The natural containment of ovarian cancer to the peritoneal cavity makes this mileau attractive for examining the immune status within a 'malignant environment'. Such investigations have yielded further insight into host-tumor responses. Immunological strategies have been employed in ovarian cancer either as single agents or combined with chemotherapy and although achieving responses have limited success. The understanding of cytokine inter-relationships, refinement of monoclonal antibody therapy and the potential genetic manipulation will enhance immunological strategies. This review will address aspects of our present knowledge of immune status in ovarian cancer, examine clinical studies incorporating immune agents and potential future therapies.

Related Articles